By
AmyT on
January 17, 2012
In the area of beta cell preservation, there’s a (sort of) new name in the spotlight: Andromeda Biotech, Ltd. with its DiaPep277 treatment. Based in Israel, this company announced last month that phase III clinical trials showed significant preservation of C-peptide levels, a marker for assessing insulin secretion by pancreatic cells. Andromeda joins the ranks of companies like Tolerx and Macrogenics/Lilly, who’ve been vocal about their work to preserve beta cell functioning in newly diagnosed patients…
Read more »
We were familiar with the company ViaCyte through its former identity as NovoCell, when we reported that they’d managed to successfully control diabetes in mice using embryonic stem cells back in 2008.
Last year, they changed their name, but their two-part mission remained the same: first, to create fully functioning beta cells (the specific kind of islet cells that make insulin and amylin) from embryonic stem cells, and then to find a way to combat…
Read more »
This past weekend, 17 of the leading researchers in the diabetes community traveled to San Diego, CA, to speak at TEDxDelMar, an exciting day-long conference focused on the latest breakthroughs and continuing challenges in the search for a cure. Although the cure was the main focus of the day, TEDxDelMar also featured discussions on living well with diabetes (with talks including Dr. Steve Edelman and Dr. Bill Polonsky) and the future of diabetes technology (with…
Read more »
We received a whopping 210 responses to our reader survey* about the possibility of wearing an implantable insulin pump last week: Would You, If You Could? We thought you might like to know the results, below.
ALSO: we received some additional feedback from Medtronic’s Chief Medical Officer Dr. Fran Kaufman about the development of this device, sent to us by PR Manager Karrie Hawbaker. We decided this would be more visible if published in a…
Read more »
